Multiple Endocrine Neoplasia Type 1
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q1 2028.
Clinical MilestonesViewHide
- 2026-03-19A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid TumorsResults expected Q1 2028
- 2026-03-19ClinicalA Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid TumorsResults expected Q1 2028
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Lung Neoplasms1
- Melanoma1
- Multiple Endocrine Neoplasia Type 11
- Neoplasms1
Leading journals1
- CA: a cancer journal for clinicians1
Leading researchers4
- Jemal A1
- Miller KD1
- Siegel RL1
- Wagle NS1
Reference
Authoritative identity, definition & identifiers.
A form of multiple endocrine neoplasia that is characterized by the combined occurrence of tumors in the PARATHYROID GLANDS, the PITUITARY GLAND, and the PANCREATIC ISLETS. The resulting clinical signs include HYPERPARATHYROIDISM; HYPERCALCEMIA; HYPERPROLACTINEMIA; CUSHING DISEASE; GASTRINOMA; and ZOLLINGER-ELLISON SYNDROME. This disease is due to loss-of-function of the MEN1 gene, a tumor suppressor gene (GENES, TUMOR SUPPRESSOR) on CHROMOSOME 11 (Locus: 11q13).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.